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LETTERS
Paris staging system for primary
gastrointestinal lymphomas
Currently, much effort is put into the develop-
ment of specific therapeutical approaches that
are tailored to specific lymphoma entities. As a
consequence,more specific information needs
to be collected to support the choice of
therapy. In gastric marginal zone B cell
lymphoma of MALT-type, the need for special-
ised documentation of tumour extent in the
organ wall has been stressed by the high pre-
dictive value for failure of response after
Helicobacter pylori eradication of infiltration
beyond the mucosa, a predictive parameter
irrespective of the presence of the t(11;18)
translocation.1–5 With new techniques such as
endosonography, this infiltration depth can be
assessed with improving accuracy. However,
the information cannot be translated into the
current staging systems. The dissemination
patterns of extranodal lymphomas are also
essentially different from primary nodal
lymphomas.6 As tumour stage is one of the
most important guidelines in the choice of
local therapy (surgery, radiotherapy) and
chemotherapy, adequate documentation of
tumour localisation in the organ related
lymph nodes and beyond is essential.
The Ann Arbor staging system, developed
for and routinely used in nodal non-
Hodgkin’s lymphoma, is not optimal for
documentation of the specific relevant fea-
tures of primary extranodal lymphoma in the
gastrointestinal tract. Several modifications
and alternatives have been proposed. How-
ever, neither differentiation of stage I1 (con-
finement of lymphoma to the mucosa and
submucosa) from stage I2 (tumour extension
beyond the submucosa according to Radaszk-
iewicz and colleagues7) nor discrimination of
stage II1 (involvement of regional lymph
nodes) from stage II2 (node involvement
beyond the regional area, as assessed in the
Musshoff modification8) is sufficiently serving
the demand for documenting all features of
lymphoma. To meet these shortcomings, the
Lugano classification was constructed by
Rohatiner and colleagues9 introducing stage
IIE for “serosa penetration” without lymph
node involvement into the Ann Arbor system.
This represents a change in meaning of stage
II that originally indicated lymph node
involvement. Therefore, the Lugano system is
causing more confusion than benefit.
TNM staging for tumours of epithelial
origin has also been proposed as an alterna-
tive in gastrointestinal lymphoma to describe
localised disease. The “T” part of this system
pertains to the anatomical structure of the
organs and sufficiently fulfills the require-
ments for staging of local extent of the
disease.
The European Gastro-Intestinal Lymphoma
Study Group (EGILS) is a multidisciplinary
group of investigators, including clinical in-
vestigators such as gastroenterologists, medi-
cal oncologists, radiotherapists, and patholo-
gists, as well as basic researchers such as
cellular and molecular biologists. Several
groups from the UK, France, Germany, the
Netherlands, Spain, and Austria now take
part and have come together regularly since
1999 to discuss and study subjects in epidemi-
ology and molecular and cell biology of
gastrointestinal lymphoma. Clinical protocols
and trials have been developed and performed
as a collaborative effort. As a result of discus-
sions on staging protocols and reporting
systems over the past years, we would like to
propose a modified TNM staging system,
named after the first venue of the group in
Paris. The staging system adequately records:
(1) depth of tumour infiltration; (2) extent of
nodal involvement; as well as (3) specific
lymphoma spreading (table 1). It is adjusted
to the gastrointestinal origin of the
lymphoma, considering histopathological
characteristics of extranodal B and T cell lym-
phomas. The use of this system in future
studies will permit accurate comparison of the
reported cohorts and should allow rapid
accumulation of good data for proper stratifi-
cation of patients for risk assessment and
treatment options.
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Table 1 Paris staging system for primary gastrointestinal lymphomas*†
TX Lymphoma extent not specified
TO No evidence of lymphoma
T1 Lymphoma confined to the mucosa/submucosa
T1m Lymphoma confined to mucosa
T1sm Lymphoma confined to submucosa
T2 Lymphoma infiltrates muscularis propria or subserosa
T3 Lymphoma penetrates serosa (visceral peritoneum) without invasion of
adjacent structures
T4 Lymphoma invades adjacent structures or organs
NX Involvement of lymph nodes not assessed
NO No evidence of lymph node involvement
N1‡ Involvement of regional lymph nodes
N2 Involvement of intra-abdominal lymph nodes beyond the regional area
N3 Spread to extra-abdominal lymph nodes
MX Dissemination of lymphoma not assessed
MO No evidence of extranodal dissemination
M1 Non-continuous involvement of separate site in gastrointestinal tract (eg,
stomach and rectum)
M2 Non-continuous involvement of other tissues (eg, peritoneum, pleura) or
organs (eg, tonsils, parotid gland, ocular adnexa, lung, liver, spleen, kidney,
breast etc.)
BX Involvement of bone marrow not assessed
B0 No evidence of bone marrow involvement
B1 Lymphomatous infiltration of bone marrow
TNM Clinical staging: status of tumour, node, metastasis, bone marrow
pTNMB Histopathological staging: status of tumor, node, metastasis, bone marrow
pN The histological examination will ordinarily include 6 or more lymph nodes
*Valid for lymphomas originating from the gastro-oesophageal junction to the anus (as defined by
identical histomorphological structure).
†In case of more than one visible lesion synchronously originating in the gastrointestinal tract, give
the characteristics of the more advanced lesion.
‡Anatomical designation of lymph nodes as “regional” according to site:
(a) stomach: perigastric nodes and those located along the ramifications of the coeliac artery (that
is, left gastric artery, common hepatic artery, splenic artery) in accordance with compartments I
and II of the Japanese Research Society for Gastric Cancer (1995);
(b) duodenum: pancreaticoduodenal, pyloric, hepatic, and superior mesenteric nodes;
(c) jejunum/ileum: mesenteric nodes and, for the terminal ileum only, the ileocolic as well as the
posterior caecal nodes;
(d) colorectum: pericolic and perirectal nodes and those located along the ileocolic, right, middle,
and left colic, inferior mesenteric, superior rectal, and internal iliac arteries.
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A new cause for CA19.9
elevation: heavy tea
consumption
Serum carbohydrate associated antigen
(CA19.9) is a reliable tumour marker of
biliopancreatic malignancies. A number of
benign diseases are also known to be related
to CA19.9 elevation. Here we report a case of
markedly raised levels of CA19.9 associated
with heavy tea consumption.
Case report
A 52 year old woman was referred to our unit
for epigastric pain and anorexia of two
months’ duration. She also complained of
nausea and a 2 kg weight loss. Her past medi-
cal history was unremarkable. She was a non-
smoker and denied alcohol abuse or medi-
cation intake but remarked on
overconsumption of warm black tea for
several months (1.5–2 litres/day). Physical
examination was normal.
Laboratory data demonstrated normal
ranges for electrolytes, liver function tests,
blood count, urea, creatinin, C reactive pro-
tein, amylase, and lipase. Fasting blood
glucose, triglycerides, cholesterol, and thyroid
function tests were normal. Autoantibodies
were negative. Serum CA19.9 was 1432 UI/ml
(normal <37), and CEA was 2 ng/ml(normal
<5).
Upper endoscopy, colonoscopy, and barium
study of the small bowel showed normal
results. Abdominal ultrasonography and com-
puted tomography scan found mild enlarge-
ment of the body of the pancreas without
hepatobiliary abnormalities. Endoscopic ul-
trasonography showed no pancreatic malig-
nancy or biliary abnormalities. The pancreas
was homogenous and mildly enlarged in the
body without pathological significance.
Spirometry, chest x ray, bronchoscopy, and
bronchoalveolar lavage fluid examination
were normal.
The patient was advised to stop tea con-
sumption. Four weeks later she became
symptom free and gained the 2 kg weight loss.
Another serum CA19.9 assay showed a
considerable drop in levels to 42 UI/ml. A
rechallenge test was then attempted. The
patient restarted tea consumption as previ-
ously. Four weeks later CA19.9 increased to
745 UI/ml followed by a fall to 25 UI/ml one
month after withdrawal. Follow up one year
later revealed no clinical abnormalities. Ab-
dominal and chest computed tomography
scan were normal.
Discussion
CA 19.9 (sialyl lewis-a) is a monosialoganglio-
side with small increases in a number of
benign diseases,with highest levels in pancre-
atic adenocarcinoma, hepatocellular, and
cholangiocellular cancer, and also in gastric,
colorectal, and occasionally other cancers.1
Physiologically elevated concentrations are
present in many secretions of healthy indi-
viduals with the Lewis a positive phenotype in
contrast with low serum levels of CA19.9 in
Lewis a negative individuals (7–10%).1
Among non-malignant causes, obstructive
jaundice is frequently associated with in-
creases in CA19.9. Relief of jaundice is often
associated with a fall in CA19.9 in benign
cases and mostly in patients with
malignancy.2 Normal biliary epithelial cells
secrete mucins carrying the epitope of CA
19.9. Unspecific elevation of CA 19.9 in serum
reflects both inflammatory hypersecretion
and leakage of biliary mucins into serum.3
In addition, there is a strong correlation
between serum CA19.9 concentration and
standard parameters of cholestasis; alkaline
phosphatase and bilirubin during acute liver
failure, acute hepatitis, and chronic liver
diseases of any aetiology.4–6
Other benign causes of CA19.9 increases
are shown in table 1. The common underlying
mechanism for each is probably inflammatory
hypersecretion of CA19.9 by normal epithelial
cells.
The constituent flavonoids of tea beverage
are known to be potent antioxidants. It
appears that the flavonoids impact on a wide
range of molecular targets that influence cell
growth and pathways of angiogenesis.7
In this case, the usual causes of CA19.9
elevation were ruled out before a link with the
tea beverage was suspected. After tea con-
sumption withdrawal, a dramatic improve-
ment occurred and the patient became symp-
tom free, suggesting the diagnosis of tea
intoxication. At the same time, serum CA19.9
levels dropped and a positive rechallenge test
proved the relationship between tea overcon-
sumption and raised levels of CA19.9.
To our knowledge, this is the first reported
case of markedly raised levels of CA19.9 asso-
ciated with heavy tea consumption. The
mechanism of this relation remains unclear.
In addition, the epithelial tissue target in-
volved in CA19.9 secretion by tea overuse is
unknown. Individual susceptibility to abnor-
mal CA19.9 secretion triggered by tea over-
consumption could not be excluded.
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Table 1 Non-malignant causes of CA19.9 elevation (medline research)
Aetiology
Serum CA19.9 level
Mild elevation
(<200 U/ml)
High levels
(>1000 U/ml)
Obstructive jaundice2 3 +
Acute liver failure and acute hepatitis4 5 +
Chronic liver disease4 +
Alcoholic liver disease4–6 + +
Non-alcoholic liver disease4 5 +
Pancreatitis
Acute8 9 + +
Chronic8 9 +
Diabetes mellitus10 +
Interstitial pulmonary disease11 +
Collagen vascular diseases12 +
Anecdotally reports: hydronephrosis,13 endometriosis,14 splenic cyst,15 bronchogenic cyst,16
sigmoid diverticulitis,17 and hypothyroidism.18
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Non-alcoholic steatohepatitis
and hepatic steatosis in patients
with adult onset growth
hormone deficiency
Adult onset growth hormone (GH) deficiency
closely resembles syndrome X.1 Patients with
syndromeXoften suffer fromobesity,dyslipid-
aemia, insulin resistance, and hypertension,
and hepatic steatosis and non-alcoholic stea-
tohepatitis (NASH) have also been character-
ised as symptoms of syndrome X.2 3 However,
the relationship of GH deficiency to hepatic
steatosis and NASH remains unclear.
We looked for the presence of hepatic stea-
tosis using computer tomography (CT) in a
study of 18 patients with adult onset anterior
lobe pituitary hormone deficiency, with or
without GH deficiency. We also performed a
liver biopsy in one patient with adult onset
GH deficiency. None of the patients was posi-
tive for hepatitis B surface antigen, hepatitis C
virus antibody, antinuclear antibody, or anti-
mitochondrial antibody. The criterion used for
diagnosing hepatic steatosis was a ratio for
the liver/spleen CT value of less than 0.9.4 In
13 patients with GH deficiency, seven showed
hepatic steatosis (53.8%) while in five patients
without GH deficiency no hepatic steatosis
was present (p=0.035). Body mass index
(BMI kg/m2), serum triglyceride level (TG
mg/dl), and serum total cholesterol (T-ch
mg/dl) were similar in patients with or with-
out GH deficiency (table 1). The significance
of the per cent hepatic steatosis was evaluated
by χ2 test. BMI, TG, and T-ch were analysed
using an unpaired Student’s t test.
The male patient on whom we performed a
liver biopsy was diagnosed with GH deficiency
at 58 years old. He showed hepatic steatosis,
measured by CT, at 64 years. Serum aspartate
aminotransferase level fluctuated from 20 to
80 U/l. The patient did not have a history of
alcohol abuse but was slightly obese (BMI 30
kg/m2). Liver biopsy was performed when the
patient was 72 years old, and this showed the
presence of NASH (fig 1).
We have demonstrated that hepatic steato-
sis is more frequently observed in patients
with GH deficiency than in those without GH
deficiency. Furthermore, by liver biopsy, we
have shown that a patient with GH deficiency
also had NASH. These results indicate that
adult onset GH deficiency is a possible risk
factor for hepatic steatosis and NASH.
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Expression of thiopurine
methyltransferase in South
Asians
Azathioprine and its metabolite
6-mercaptopurine (6-MP) are widely used in
the treatment of Crohn’s disease, ulcerative
colitis, autoimmune hepatitis, and a range of
other inflammatory and autoimmune dis-
eases, as well as for prevention of transplant
rejection. Thiopurine methyltransferase
(TPMT) converts 6-MP to 6-methylMP.1 2
Deficiency of its expression predisposes
treated patients to bone marrow depression; it
may also enhance the efficacy of thiopurines
by increasing their metabolism to
6-thioguanine nucleotides.1 2 Previous reports
in Caucasians have shown that approximately
0.3% are homozygously and 10% hetero-
zygously deficient in TPMT.1 2 One study
Figure 1 Histology of the liver biopsy. Macrovesicular steatosis, pericellular and
centrilobular fibrosis, and ballooned hepatocytes are all observed in this section. (Method:
needle biopsy; haematoxylin-eosin staining.)
Table 1
Without GH
deficiency With GH deficiency p Value
Hepatic steatosis (+/−) 0/5 7/6 0.035
BMI (kg/m2) 21.29(1.2) 23.54(2.21) 0.35
TG (mg/dl) 135.8 (25) 95.4 (10) 0.30
T-ch (mg/dl) 202.5 (18) 180 (6.0) 0.44
Values are mean (SD).
BMI, body mass index; TG, serum triglyceride level; T-ch, serum total cholesterol.
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suggests that the frequency of individuals
with the mutant TPMT allele, TPMT*3A, is
lower in Southwest Asians than in Cauca-
sians3; this variant allele causes reduced
enzyme activity in vitro.3 However, there are
no data on the phenotypic expression of TPMT
in South Asian populations.
We have compared expression of TPMT in
South Asian and Caucasian patients attend-
ing gastroenterology, renal, rheumatology,
and dermatology clinics who were being con-
sidered for treatment with thiopurines. TPMT
activity was assayed by tandem mass spec-
trometry for 6-methylMP (assays kindly
provided by Purine Research Laboratory,
Guy’s Hospital, London SE1 9RT, UK). Homo-
zygous deficiency of TPMT was defined as a
level <10, heterozygous as 10–25, and normal
as > 25 pmol/h/mg haemoglobin.
Of 83 Caucasian patients, one (1.3%) was
homozygously deficient, 10 (12%) were
heterozygous, and 72 (86.7%) had normal
expression of TPMT. The corresponding values
in 77 South Asian patients were 0, 7 (9%), and
70 (91%), respectively.
The prevalence of deficiency of expression
of TPMT in South Asian patients resembles
that in Caucasians. Use and monitoring of
azathioprine and 6-MP should therefore
follow similar principles in both ethnic
groups.
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Fatigue is associated with high
circulating leptin levels in
chronic hepatitis C
We read with great interest the recent paper
from Piche and colleagues (Gut 2002;51:434–
9) relating leptin levels to fatigue in chronic
hepatitis C patients. On the surface, their
observation that serum leptin levels correlate
with the fatigue impact scale are very intrigu-
ing. However, leptin shows a gender based
difference and women have circulating
plasma leptin concentrations that are at least
three times higher than men, even when
matched for body fat mass.1 Thus sex needs to
be considered when investigating any associ-
ation with leptin levels, and multivariate
analysis is necessary to reduce the bias caused
by this confounding variable. Indeed, in the
study by Piche et al the fatigue impact scale
was found to be significantly higher in
females. Therefore, without a multivariate
analysis the authors cannot affirm that serum
leptin levels are implicated in fatigue develop-
ment in patients with chronic hepatitis C.
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Mutant K-ras2 in serum
Ryan and colleagues’ careful and well con-
ducted study (Gut 2003;52:101–8) raises once
again the interesting issue of whether mol-
ecular analysis and knowledge of mutations
of the Kirsten ras gene in particular, have a
role in the management of patients with colo-
rectal cancer.
The two RASCAL (Kirsten Ras in Colorectal
Cancer Collaborative group) studies1 2 which
eventually enrolled data from 4266 patients
from 42 centres in 21 countries showed that
although the frequency of Kirsten ras muta-
tions at codons 12 and 13 may vary a little
between populations, overall they are only
present in just over one third of patients. This
is significantly less frequent than quoted by
Ryan et al. In addition, the RASCAL study also
showed that Kirsten ras mutations are not
associated with sex, age, tumour site, or
Dukes’ stage.
Much more importantly, however, they also
showed that of the 12 different possible
specific point mutations at codons 12 or 13,
only a guanine to thymidine mutation, which
are found in less than 10% of all patients, is an
independent variable for relapse and death.
Indeed, the most common mutation, guanine
to adenine, exerted an effect on survival
barely different from wild-type ras. Others
have shown there is a reasonable biological
basis for these findings.3 4
As a collaborative group, therefore,we felt it
was generally unhelpful to consider Kirsten
ras mutations collectively, rather than the
effect of each individual mutation separately
when considering the prognosis of patients
with colorectal cancer. With this in mind, we
believe that two crucial questions are left
unanswered by the study of Ryan et al.
Without definitive answers to these, it is
unlikely that serum detection of mutated
Kirsten ras gene will ever be clinically useful.
Firstly, detection of any new mutation in
the serum of a patient who has had colorectal
cancer raises the possibility of tumour recur-
rence, although the presence of a Kirsten ras
mutation is not colon specific. However, more
than one third of patients in Ryan’s study did
not clinically relapse despite the presence of a
serum mutation for very long periods. Others
have also detected tumour DNA in patients for
long periods without evidence of overt clinical
recurrence.5 Therefore, screening for the pres-
ence of Kirsten ras mutations per se is
unlikely to be clinically helpful very often.
However, it would have been very interesting
to know whether the patients who did not
relapse in this study were those who had what
the RASCAL group have defined as “benign”
rather than “aggressive” mutations.
Secondly, the authors do not say whether
each postoperative serum mutation which
they detected corresponded with the geno-
type of the primary tumour. While a number
of studies have suggested that occasional
metastases may carry a different mutation to
the primary, this is very uncommon. If the
mutation is not the same as the primary
tumour, this raises many issues, not least that
despite the very careful use of controls, nested
polymerase chain reaction techniques may be
too sensitive for clinical practice.
For an individual with colorectal cancer, a
multitude of factors may shape the clinical
course. To improve our knowledge, we must
seek to study the most subtle variation in
molecular profiles possible, as small differ-
ences may be very important. While rigorous
small prognostic clinical studies may be
intriguing, they may have significant limita-
tions. Some of us have argued previously that
there is only one way forward.6 All bodies
funding prospective therapeutic studies in
colorectal cancer should insist that a panel of
molecular markers are measured and re-
corded in all patients using a standardised
technique, even if they are not included as an
end point, and make these results readily
available for subsequent analysis. Studies
which are performed prospectively carry the
least risk of methodological flaws.
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BOOK REVIEW
Radiological Imaging of the
Small Intestine
Edited by N C Gourtsoyiannis. Berlin:
Springer, 2002, €214.0, pp 477. ISBN
3-540- 65520-4
Springer Verlag are producing an extensive
range of books entitledMedical Radiology under
the general editorship of Professor AL Baert,
and this volume on the small intestine is the
latest in the line. Professor NC Gourtsoyiannis
is its distinguished editor. This is now a very
well established series with topics which vary
from organ based (that is, pancreas) to
technique based (that is, spiral computed
tomograpy (CT)) of the abdomen. As with all
Springer publications, the illustrations are
outstanding and the more than 800 in this
book are no exception.
Imaging of the small intestine remains the
last redoubt for the gastrointestinal radiolo-
gist due to the remorseless advance of endos-
copy from both ends of the alimentary tract; a
point noted in the foreword by Professor
Baert. Virtual colonoscopy has rekindled
some interest but this is strictly a polyp/
tumour detection exercise and the more sub-
tle and interesting colonic abnormalities
elude it. Study of the small bowel however
retains that interest, both because of the
myriad of processes which may affect it as
well as the fact that it is not so easy to initiate
the “ knee jerk” response of biopsy it. It there-
fore remains more of a deductive radiological
process where observations need to be care-
fully integrated with the clinical state of the
patient before a reasoned differential can be
given. This coupled with the multitude of
imaging techniques, from good old fashioned
barium to ultrasound, CT, and magnetic reso-
nance (MR), etc, still means that it provides a
diagnostic challenge.
How does Radiological Imaging of the Small
Intestine help? The answer is enormously, as it
presents an encyclopaedic review of all of the
small bowel abnormalities with their attend-
ant investigative techniques. The only prob-
lem (and it is one which affects all radiologi-
cal texts) is the question of whether to go for
chapters which reflect technique or for those
which reflect pathological conditions. In this
case the editor has gone for both and while
this results in a superlative volume, there is
bound to be some repetition. For example, ref-
erence to Crohn’s disease or small bowel
tumours will appear both in their own section
as well as under CT/MR, etc. However, as all of
these chapters are written by different au-
thors with their own experiences, this can
prove to be an advantage enabling the reader
a “second bite of the cherry”.
Is there competition in the market place
and how does this book hold up? The inevita-
ble comparison has to be made to Clinical
Imaging of the Small Intestine by Herlinger,
Maglinte, and Birnbaum, interestingly also
published by Springer. This is the more
mature book, now in its second edition,
having been originally published in 1989. Its
authorship is primarily North American with
two European contributors whereas Radiologi-
cal Imaging is primarily a European work with
some distinguished North American con-
tributors. Indeed, two of the editors of Clinical
Imaging are authors. Both books go for the
same layout—that is, chapters which are
technique based followed by those on patho-
logical states. Both are totally comprehensive
and although Clinical Imaging is slightly larger
(576 pp versus 477 pp) it is less expensive
(€164 versus €214 ). This price differential is
most likely to be due to the inclusion of 141
beautiful colour illustrations of both endo-
scopic views and pathology specimens in
Radiological Imaging. This is also the most
recent publication (2002 versus 1999) and in
areas where there is rapid technical change—
typically MR imaging—the reader can appre-
ciate the difference. It has to be said that both
books fulfil their remit extremely well but
your reviewer, if he had to choose, would opt
for spending the extra Euros.
Professor Gourtsoyiannis and his team have
to be congratulated on producing a superb
book that graces the swelling ranks of medical
radiology. A must for every radiology depart-
ment and a continuing source of information
for any radiologist with an interest in the
gastrointestinal system
A H Freeman
NOTICES
New In Vivo Imaging Modalities
for Molecular Biology, Cell
Biology and Physiology
This Jacques Monod conference will be held
on 31 May–4 June 2003 in Roscoff, France.
Further information: Bertrand Tavitian, IN-
SERM M10103, Service Hospitalier Frédéric
Joliot, CEA Direction des Sciences du Vivant,
Direction de la RechercheMédicale, 4 place du
Général Leclerc, 91401 Orsay Cedex, France.
Tel: +33 169 867 779; fax: +33 169 867 739;
email: tavitian@shfj.cea.fr
Prague Hepatology Meeting
To be held on 5–7 June 2003 in Prague, Czech
Republic. Leading speakers from Europe and
the USA will present new ideas and sugges-
tions on pathophysiology, diagnostics, and
therapy of liver diseases in ten programmes
blocks. Further details: Ms Veronica Revicka.
Tel: +420 241 445 759; fax:+420 241 445 806;
email: veronika@congressprague.cz
8th International Liver
Symposium
This symposium will be held on 13 June 2003
inManchester, UK. Leading speakers from the
USA and Europe will present state of the art
reviews on recent advances in hepatology.
Further details: Professor TWWarnes, Depart-
ment of Gastroenterology, Manchester Royal
Infirmary, Oxford Road, Manchester
M13 9WL, UK. Tel: +44 (0)161 276 4316; fax:
+44 (0)161 276 8779; email:
judith.harrop@cmmc.nhs.uk
Falk Symposia—New Findings
on Pathogenesis and Progress in
Management of IBD
Two symposia and a workshop will be held on
10–14 June 2003 in Berlin, Germany. Further
details: Falk Foundation e.V., Congress Divi-
sion, PO Box 6529, Leinenweberstr. 5, 79041
Freiburg/Br, Germany. Tel: +49 761 15 140;
fax: +49 761 15 14 359; email:
symposia@falkfoundation.de; website: www-
.falkfoundation.de
Gastroenterology and
Endotherapy: XXIst European
Workshop
This will be held on 16–18 June 2003 in Brus-
sels, Belgium. Further details: Nancy Beaup-
rez, Administrative Secretariat of the Work-
shop, Gastroenterology Department, Erasme
Hospital, Route de Lennik 808, B-1070
Brussels, Belgium. Tel: +32 (0)2 555 49 00;
fax: +32 (0)2 555 49 01; email:
beauprez@ulb.ac.be
The Association of
Coloproctology of Great Britain
& Ireland
This annual meeting will be held on 7–10 July
2003 in Edinburgh, UK. Further details: Con-
ference Secretariat, The ACGBI at the Royal
College of Surgeons of England, 35–43 Lin-
coln’s Inn Fields, London WC2A 3PE. Tel: +44
(0)20 7973 0307; fax: +44 (0)20 7430 9235;
email: acpgbi@asgbi.org.uk; website: ww-
w.acpgbi.org.uk
European Helicobacter Study
Group (EHSG)
This meeting, on Helicobacter infections and
gastroduodenal pathology, will be held on 3–6
September 2003 in Stockholm, Sweden. Fur-
ther details: Professor Torkel Wadstrom,
President- EHSG, Lund University, Depart-
ment of Infectious Diseases & Medical Micro-
biology, Division of Bacteriology, Solvegatan
23, SE-223 62 Lund, Sweden. Tel: +46 46 173
241; fax: +46 46 152 564; email:
Torkel.Wadstrom@mmb.lu.se; website: ww-
w.helicobacter.org
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